Anemia of inflammation (AI) is a common comorbidity in hemodialysis patients. Paricalcitol is
a selective vitamin D receptor activator with potential benefits on anti-inflammatory
cytokines expression. The paricalcitol for the secondary hyperparathyroidism control may
improve AI decreasing erythropoietin stimulating agents (ESAs) dosage.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Son Espases
Treatments:
Epoetin Alfa Ergocalciferols Hematinics Vitamin D Vitamins